Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma

• Published in: Cancer science Vol. 111; no. 7; pp. 2460 - 2471
• Main Authors: Osawa, Takahiro, Kojima, Takahiro, Hara, Tomohiko, Sugimoto, Mikio, Eto, Masatoshi, Takeuchi, Ario, Minami, Keita, Nakai, Yasutomo, Ueda, Kosuke, Ozawa, Michinobu, Uemura, Motohide, Miyauchi, Yasuyuki, Ohba, Kojiro, Suzuki, Toshiro, Anai, Satoshi, Shindo, Tetsuya, Kusakabe, Naohisa, Tamura, Keita, Komiyama, Motokiyo, Goto, Takayuki, Yokomizo, Akira, Kohei, Naoki, Kashiwagi, Akira, Murakami, Masaya, Sazuka, Tomokazu, Yasumoto, Hiroaki, Iwamoto, Hideto, Mitsuzuka, Koji, Morooka, Daichi, Shimazui, Toru, Yamamoto, Yoshiaki, Ikeshiro, Suguru, Nakagomi, Hiroshi, Morita, Ken, Tomida, Ryotaro, Mochizuki, Tango, Inoue, Takamitsu, Kitamura, Hiroshi, Yamada, Shuhei, Ito, Yoichi M., Murai, Sachiyo, Nishiyama, Hiroyuki, Shinohara, Nobuo
• Format: Journal Article
• Language: English
• Published: Tokyo John Wiley & Sons, Inc 01.07.2020; John Wiley and Sons Inc
• Subjects: axitinib; Cancer therapies; Clinical trials; Drug dosages; Immunotherapy; Kidney cancer; Laboratories; Lymphocytes; Medical prognosis; Metastases; Metastasis; metastatic; Neutrophils; Oncology; Original; Patients; Population studies; prognostic factor; Renal cell carcinoma; Risk groups; risk model; Survival analysis; Vascular endothelial growth factor
• ISSN: 1347-9032; 1349-7006
• DOI: 10.1111/cas.14449

The present study aimed to evaluate the efficacy of the real‐world use of axitinib and to develop a prognostic model for stratifying patients who could derive long‐term benefit from axitinib. This was a retrospective, descriptive study evaluating the efficacy of axitinib in patients with metastatic renal cell carcinoma that had been treated with 1 or 2 systemic antiangiogenic therapy regimens at 1 of 36 hospitals belonging to the Japan Urologic Oncology Group between January 2012 and February 2019. The primary outcome was overall survival (OS). Using a split‐sample method, candidate variables that exhibited significant relationships with OS were chosen to create a model. The new model was validated using the rest of the cohort. In total, 485 patients were enrolled. The median OS was 34 months in the entire study population, whereas it was not reached, 27 months, and 14 months in the favorable, intermediate, and poor risk groups, respectively, according to the new risk classification model. The following 4 variables were included in the final risk model: the disease stage at diagnosis, number of metastatic sites at the start of axitinib therapy, serum albumin level, and neutrophil : lymphocyte ratio. The adjusted area under the curve values of the new model at 12, 36, and 60 months were 0.77, 0.82, and 0.82, respectively. The efficacy of axitinib in routine practice is comparable or even superior to that reported previously. The patients in the new model’s favorable risk group might derive a long‐term survival benefit from axitinib treatment. The accuracy of the overall survival predictions made after the initiation of axitinib treatment, area under the curve (AUC) values were calculated for each model. The adjusted AUC values at 12, 36, and 60 months after the initiation of axitinib were 0.77, 0.82, and 0.82, respectively, for the axitinib treatment prediction model, and 0.69, 0.67 and 0.56, respectively, for the International Metastatic Renal Cell Carcinoma Database Consortium model.